Last Updated: September 24, 2026

Amgen Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for AMGEN

AMGEN has six approved drugs.

There are twenty-five US patents protecting AMGEN drugs.

Summary for Amgen

US Patents:	25
Tradenames:	5
Ingredients:	5
NDAs:	6
Patent Litigation for Amgen:	See patent lawsuits for Amgen
PTAB Cases with Amgen as petitioner:	See PTAB cases with Amgen as petitioner
PTAB Cases with Amgen as patent owner:	See PTAB cases with Amgen as patent owner

Drugs and US Patents for Amgen

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amgen Inc	LUMAKRAS	sotorasib	TABLET;ORAL	214665-002	Jan 20, 2023		RX	Yes	Yes		⤷ Start Trial				⤷ Start Trial
Amgen Inc	OTEZLA	apremilast	TABLET;ORAL	205437-002	Mar 21, 2014	AB	RX	Yes	No		⤷ Start Trial				⤷ Start Trial
Amgen Inc	CORLANOR	ivabradine	SOLUTION;ORAL	209964-001	Apr 22, 2019		DISCN	Yes	No	7,879,842	⤷ Start Trial	Y	Y		⤷ Start Trial
Amgen Inc	LUMAKRAS	sotorasib	TABLET;ORAL	214665-003	Jun 26, 2024		RX	Yes	No		⤷ Start Trial				⤷ Start Trial
Amgen Inc	OTEZLA	apremilast	TABLET;ORAL	205437-003	Mar 21, 2014	AB	RX	Yes	Yes	12,576,034*PED	⤷ Start Trial			Y	⤷ Start Trial
Amgen Inc	OTEZLA	apremilast	TABLET;ORAL	205437-003	Mar 21, 2014	AB	RX	Yes	Yes	7,427,638*PED	⤷ Start Trial			Y	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Amgen

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Amgen Inc	OTEZLA	apremilast	TABLET;ORAL	205437-001	Mar 21, 2014	9,018,243	⤷ Start Trial
Amgen Inc	OTEZLA	apremilast	TABLET;ORAL	205437-001	Mar 21, 2014	8,802,717	⤷ Start Trial
Amgen Inc	OTEZLA	apremilast	TABLET;ORAL	205437-002	Mar 21, 2014	9,724,330	⤷ Start Trial
Amgen Inc	OTEZLA	apremilast	TABLET;ORAL	205437-002	Mar 21, 2014	6,020,358	⤷ Start Trial
Amgen Inc	OTEZLA	apremilast	TABLET;ORAL	205437-003	Mar 21, 2014	6,962,940	⤷ Start Trial
Amgen	SENSIPAR	cinacalcet hydrochloride	TABLET;ORAL	021688-002	Mar 8, 2004	6,031,003	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for AMGEN drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	30 mg, 60 mg and 90mg	➤ Subscribe	2008-03-10
➤ Subscribe	Tablets	10 mg, 20 mg and30 mg	➤ Subscribe	2018-03-22

International Patents for Amgen Drugs

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Montenegro	02747	⤷ Start Trial
European Patent Office	2316442	⤷ Start Trial
Poland	3630761	⤷ Start Trial
Cyprus	1109380	⤷ Start Trial
Lithuania	2797581	⤷ Start Trial
Brazil	PI0600796	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for Amgen Drugs

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2962690	132019000000096	Italy	⤷ Start Trial	PRODUCT NAME: APREMILAST(OTEZLA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/981, 20150116
2962690	2019C/008	Belgium	⤷ Start Trial	DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CESSION
2962690	CR 2019 00033	Denmark	⤷ Start Trial	PRODUCT NAME: APREMILAST ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/981 20150116
2962690	C20190029 00295	Estonia	⤷ Start Trial	PRODUCT NAME: APREMILAST;REG NO/DATE: EU/1/14/981 16.01.2015
1203761	05C0029	France	⤷ Start Trial	PRODUCT NAME: CINACALCET; REGISTRATION NO/DATE: EU/01/04/292/001-012 20041022
2962690	300994	Netherlands	⤷ Start Trial	DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.